Sign In
Buy AUNA
Auna Sa Earnings Calls
| Release date | May 19, 2026 |
| EPS estimate | $0.190 |
| EPS actual | $0.0257 |
| EPS Surprise | -86.47% |
| Revenue estimate | 320.541M |
| Revenue actual | 336.41M |
| Revenue Surprise | 4.95% |
| Release date | Mar 10, 2026 |
| EPS estimate | $0.130 |
| EPS actual | $0.530 |
| EPS Surprise | 307.69% |
| Revenue estimate | 325.242M |
| Revenue actual | 336.671M |
| Revenue Surprise | 3.51% |
| Release date | Nov 20, 2025 |
| EPS estimate | $0.150 |
| EPS actual | $0.200 |
| EPS Surprise | 33.33% |
| Revenue estimate | 1.079B |
| Revenue actual | 316.085M |
| Revenue Surprise | -70.71% |
| Release date | Aug 19, 2025 |
| EPS estimate | $0.130 |
| EPS actual | $0.330 |
| EPS Surprise | 153.85% |
| Revenue estimate | 1.174B |
| Revenue actual | 308.392M |
| Revenue Surprise | -73.73% |
Last 4 Quarters for Auna Sa
Below you can see how AUNA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 19, 2025 |
| Price on release | $6.30 |
| EPS estimate | $0.130 |
| EPS actual | $0.330 |
| EPS surprise | 153.85% |
| Date | Price |
|---|---|
| Aug 13, 2025 | $6.30 |
| Aug 14, 2025 | $6.32 |
| Aug 15, 2025 | $6.31 |
| Aug 18, 2025 | $6.24 |
| Aug 19, 2025 | $6.30 |
| Aug 20, 2025 | $6.31 |
| Aug 21, 2025 | $6.28 |
| Aug 22, 2025 | $6.18 |
| Aug 25, 2025 | $6.22 |
| 4 days before | 0% |
| 4 days after | -1.27% |
| On release day | 0.159% |
| Change in period | -1.27% |
| Release date | Nov 20, 2025 |
| Price on release | $4.83 |
| EPS estimate | $0.150 |
| EPS actual | $0.200 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| Nov 14, 2025 | $5.18 |
| Nov 17, 2025 | $5.00 |
| Nov 18, 2025 | $5.13 |
| Nov 19, 2025 | $4.92 |
| Nov 20, 2025 | $4.83 |
| Nov 21, 2025 | $4.73 |
| Nov 24, 2025 | $4.74 |
| Nov 25, 2025 | $4.64 |
| Nov 26, 2025 | $4.78 |
| 4 days before | -6.76% |
| 4 days after | -1.04% |
| On release day | -2.07% |
| Change in period | -7.72% |
| Release date | Mar 10, 2026 |
| Price on release | $4.80 |
| EPS estimate | $0.130 |
| EPS actual | $0.530 |
| EPS surprise | 307.69% |
| Date | Price |
|---|---|
| Mar 04, 2026 | $5.06 |
| Mar 05, 2026 | $4.95 |
| Mar 06, 2026 | $4.83 |
| Mar 09, 2026 | $4.77 |
| Mar 10, 2026 | $4.80 |
| Mar 11, 2026 | $5.16 |
| Mar 12, 2026 | $4.98 |
| Mar 13, 2026 | $5.09 |
| Mar 16, 2026 | $5.18 |
| 4 days before | -5.14% |
| 4 days after | 7.92% |
| On release day | 7.50% |
| Change in period | 2.37% |
| Release date | May 19, 2026 |
| Price on release | $4.75 |
| EPS estimate | $0.190 |
| EPS actual | $0.0257 |
| EPS surprise | -86.47% |
| Date | Price |
|---|---|
| May 13, 2026 | $4.89 |
| May 14, 2026 | $5.01 |
| May 15, 2026 | $4.80 |
| May 18, 2026 | $4.86 |
| May 19, 2026 | $4.75 |
| May 20, 2026 | $4.38 |
| May 21, 2026 | $4.39 |
| May 22, 2026 | $4.31 |
| May 26, 2026 | $4.25 |
| 4 days before | -2.86% |
| 4 days after | -10.53% |
| On release day | -7.79% |
| Change in period | -13.09% |
Auna Sa Earnings Call Transcript Summary of Q1 2026
Auna started 2026 with 10% FX-neutral revenue growth driven by improved volumes and higher-complexity services across Mexico, Peru and Colombia. Consolidated adjusted EBITDA fell 5% FXN and margins contracted ~2.9pp, primarily due to two one-off/extraordinary items: revenue adjustments (penalties/reconciliations) and delayed pharmacy rebates in Peru, plus payroll increases (leadership hires and minimum wage effects). Segment highlights: Mexico recovered strongly (revenues +8%, surgery and oncology utilization rising, ISSSTELEON contract renegotiated) with notable sequential EBITDA recovery; Peru revenues +9% with OncoSalud B2B growth but near-term profit pressure from payer reconciliations and rebate timing; Colombia grew fastest (+13%) thanks to expanding risk‑sharing agreements (PGP) and reduced exposure to intervened payers. Cash and balance-sheet: leverage at 3.7x (impacted by noncash FX), cash balance up 22% to PEN 409m, free cash flow PEN 152m (2.6x yoy), and continued focus on supplier financing and working-capital initiatives. Hedging repositioned to reduce FX volatility. Management reaffirmed full-year revenue and adjusted EBITDA guidance, expects stronger second-half performance, plans to start construction on Torre Trecca (ambulatory tower in Lima) imminently, and continues to prioritize cash generation while evaluating capital allocation (including potential buybacks) subject to Board review.
